Evidence map›Paper›PMID 32633484›Full record

ArticleACS chemical biology2020

Inhibition and Crystal Structure of the Human DHTKD1-Thiamin Diphosphate Complex.

João Leandro, Susmita Khamrui, Hui Wang, Chalada Suebsuwong, Natalia S Nemeria, Khoi Huynh, Moses Moustakim, Cody Secor, May Wang, Tetyana Dodatko and 9 more

Open access · greenAbstract readLetter
In one paragraph

Article in ACS chemical biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. HeterozygousGenes · 2021
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

João LeandroDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-0163-3235
Susmita KhamruiDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Hui WangDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Chalada SuebsuwongDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Natalia S NemeriaDepartment of Chemistry, Rutgers, The State University of New Jersey, Newark, New Jersey 07102, United States.
Khoi HuynhDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Moses MoustakimDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Cody SecorDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
May WangDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Tetyana DodatkoDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Brandon StaufferMount Sinai Genomics, Inc, Stamford, Connecticut 06902, United States.
Christopher G WilsonSmall Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.
Chunli YuDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Michelle R ArkinSmall Molecule Discovery Center and Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, United States.ORCID 0000-0002-9366-6770
Frank JordanDepartment of Chemistry, Rutgers, The State University of New Jersey, Newark, New Jersey 07102, United States.
Roberto SanchezDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.
Robert J DeVitaDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-2671-8497
Michael B LazarusDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-6738-2563
Sander M HoutenDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States.ORCID 0000-0002-6167-9147
Icahn School of Medicine at Mount Sinai · USDiscovery Institute · USRutgers, The State University of New Jersey · USUniversity of California, San Francisco · US

Funding

MSHS Translational Science HubUL1TR001433 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WRIGHT, ROSALIND J · 2015 to 2019
$26.6M
Life Science and Biomedical technology Research center at NSLS-II LSBRP41GM111244 · NIGMS · BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB · PI MCSWEENEY, SEAN · 2014 to 2018
$16.4M
Chemical and structural tools to study energy homeostasis pathways in cancer and diabetesR35GM124838 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Michael Block Lazarus · 2017 to 2026
$5.2M
Novel Treatment Options for Glutaric AciduriaR21HD088775 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI DEVITA, ROBERT J, HOUTEN, SANDER MICHEL · 2017 to 2018
$466k
Genetic validation of DHTKD1 as a therapeutic target for the treatment of Glutaric Aciduria type 1R03HD092878 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOUTEN, SANDER MICHEL · 2017 to 2018
$170k
NCATS NIH HHS UL1 TR001433NICHD NIH HHS R03 HD092878NICHD NIH HHS R21 HD088775NIGMS NIH HHS P41 GM111244NIGMS NIH HHS R35 GM124838
6 · The paper itself

Abstract

DHTKD1 is the E1 component of the 2-oxoadipate dehydrogenase complex, which is an enzyme involved in the catabolism of (hydroxy-)lysine and tryptophan. Mutations in DHTKD1 have been associated with 2-aminoadipic and 2-oxoadipic aciduria, Charcot-Marie-Tooth disease type 2Q and eosinophilic esophagitis, but the pathophysiology of these clinically distinct disorders remains elusive. Here, we report the identification of adipoylphosphonic acid and tenatoprazole as DHTKD1 inhibitors using targeted and high throughput screening, respectively. We furthermore elucidate the DHTKD1 crystal structure with thiamin diphosphate bound at 2.25 Å. We also report the impact of 10 disease-associated missense mutations on DHTKD1. Whereas the majority of the DHTKD1 variants displayed impaired folding or reduced thermal stability in combination with absent or reduced enzyme activity, three variants showed no abnormalities. Our work provides chemical and structural tools for further understanding of the function of DHTKD1 and its role in several human pathologies.

Indexed as

Circular DichroismCrystallography, X-RayHumansKetoglutarate Dehydrogenase ComplexMolecular StructureMutation, MissenseThiamine PyrophosphateDHTKD1 protein, humanKetoglutarate Dehydrogenase ComplexThiamine Pyrophosphate

Identifiers

PMID32633484
PMCPMC7890914
OpenAlexW3041827672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.